Final version of 2009 AJCC melanoma staging and classification.
暂无分享,去创建一个
Jeffrey E Gershenwald | Merrick I Ross | Charles M Balch | Michael B Atkins | Keith T Flaherty | Martin C Mihm | V. Sondak | M. Mihm | M. Ross | K. Flaherty | P. Gimotty | M. Atkins | J. Kirkwood | A. Cochran | A. Eggermont | J. Gershenwald | C. Balch | A. Buzaid | S. Soong | D. Coit | K. McMasters | D. Morton | A. Sober | D. Byrd | John F. Thompson | Kelly M McMasters | Shouluan Ding | Alistair J Cochran | Phyllis A Gimotty | Seng-Jaw Soong | John M Kirkwood | John F Thompson | Vernon K Sondak | David R Byrd | Antonio C Buzaid | Daniel G Coit | Shouluan Ding | Alexander M Eggermont | Donald L Morton | Arthur J Sober | J. Thompson
[1] D. Elder,et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Cascinelli,et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Busam. The Prognostic Importance of Tumor Mitotic Rate for Patients with Primary Cutaneous Melanoma , 2004, Annals of Surgical Oncology.
[4] M. Ross,et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Halpern,et al. A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma , 2007, Annals of Surgical Oncology.
[6] A. Cochran,et al. Immunohistochemical characteristics of melanoma , 2008, Journal of cutaneous pathology.
[7] M. Ross,et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. F. Charles M. Balch MD. Microscopic Satellites Around a Primary Melanoma: Another Piece of the Puzzle in Melanoma Staging , 2009, Annals of Surgical Oncology.
[9] D. Coit,et al. Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status , 2002, Annals of Surgical Oncology.
[10] E. Gershenwald. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy , 2007, Annals of Surgical Oncology.
[11] C. Balch,et al. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. , 1979, Surgery.
[12] M. Nosrati,et al. The role of microsatellites as a prognostic factor in primary malignant melanoma. , 2005, Archives of dermatology.
[13] M. Ross,et al. Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy , 2001, Annals of Surgical Oncology.
[14] D. Morton,et al. Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.
[15] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Testori,et al. Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience , 2000, Annals of Surgical Oncology.
[17] C. Balch,et al. Method of Biopsy and Incidence of Positive Margins in Primary Melanoma , 2007, Annals of Surgical Oncology.
[18] D. Morton,et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. D. Rosso. Microscopic Satellitosis in Patients with Primary Cutaneous Melanoma: Implications for Nodal Basin Staging , 2010 .
[20] Jeffrey E. Lee,et al. Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (≥4 mm) Primary Melanoma , 2000, Annals of Surgical Oncology.
[21] Jeffrey E. Lee,et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites , 2006, Cancer.
[22] J. Kirkwood,et al. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Lang. Mitotic Rate as a Predictor of Sentinel Lymph Node Positivity in Patients With Thin Melanomas , 2006 .
[24] J. Manola,et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Sondak,et al. Sentinel node biopsy and standard of care for melanoma. , 2009, Journal of the American Academy of Dermatology.
[26] D. Elder. Pathology of Melanoma , 2006, Clinical Cancer Research.
[27] A. Alavi,et al. Mitotic Rate as a Predictor of Sentinel Lymph NodePositivity in Patients With Thin Melanomas , 2004, Annals of Surgical Oncology.
[28] C. Balch,et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Gonen,et al. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis , 2005, The American journal of surgical pathology.
[31] D. Schadendorf,et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplati , 2002, European journal of cancer.
[32] Jeffrey E. Lee,et al. Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients , 2003, Annals of Surgical Oncology.
[33] R. Lyles,et al. Sentinel Lymph Node Mapping for Thick (≥4-mm) Melanoma: Should We Be Doing It? , 2003, Annals of Surgical Oncology.
[34] D. Schadendorf,et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin , 2002 .
[35] R. Scolyer,et al. The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up , 2004, Annals of Surgical Oncology.
[36] C. Balch,et al. Sentinel-node biopsy in melanoma. , 2006, The New England journal of medicine.
[37] P. Hwu,et al. Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma , 2008, Cancer investigation.